Related Experiment Video
Updated: Aug 10, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Mechanisms of disease: new mechanisms of antiarrhythmic actions
Robert F Gilmour1, Douglas P Zipes
1Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853, USA. rfg2@cornell.edu
Insights
New antiarrhythmic strategies targeting atrial and ventricular fibrillation show promise for preventing cardiac arrhythmias. Further research is needed for effective pharmacologic therapy against fatal heart rhythm disturbances.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Cardiac arrhythmias are a significant cause of death and illness globally.
- Current drug therapies for arrhythmias are often ineffective and empirical.
- There is a critical need for novel prevention strategies for cardiac arrhythmias.
Purpose of the Study:
- To review the experimental basis for promising antiarrhythmic strategies.
- To focus on strategies targeting atrial and ventricular fibrillation.
- To assess the potential for future pharmacologic treatments for cardiac arrhythmias.
Main Methods:
- Review of current experimental research on antiarrhythmic strategies.
- Focus on cellular mechanisms underlying arrhythmias.
- Evaluation of strategies targeting atrial and ventricular fibrillation.
Main Results:
- Several promising antiarrhythmic strategies are identified.
- The cellular mechanisms of most arrhythmias remain unclear.
- Current pharmacologic treatments are largely empirical.
Conclusions:
- New antiarrhythmic strategies offer cautious optimism for future treatments.
- Effective pharmacologic therapy for fatal cardiac rhythm disturbances may be achievable.
- Further research is required before clinical application of these strategies.
Abstract:
Cardiac arrhythmias are a leading cause of morbidity and mortality in many developed countries. Despite intensive investigation, the cellular mechanisms for most cardiac arrhythmias have not been clearly established. As a consequence, drug therapy for most forms of atrial and ventricular arrhythmias remains largely empirical and ineffective, leading to the increased use of nonpharmacologic treatments. Clearly, new approaches to the prevention of cardiac arrhythmias are needed. Here we review the current experimental basis for several promising antiarrhythmic strategies, with a focus on those targeted against atrial and ventricular fibrillation. Although none of these strategies is yet ready for clinical application, they provide a basis for cautious optimism that effective pharmacologic therapy for fatal cardiac rhythm disturbances could be forthcoming.
More Related Videos
09:20Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias